Unlock Clinically Predictive Insights with Biocytogen’s Orthotopic Tumor Models

December 16, 2025

Share on:

Animal models remain a critical foundation of oncology drug development. However, traditional subcutaneous xenograft models often fail to fully capture the complex biology of human tumors, particularly the influence of the native tumor microenvironment. This limitation can reduce their ability to accurately predict tumor progression, invasion, and metastatic behavior.

To address these challenges and improve translational relevance, researchers are increasingly turning to orthotopic tumor models, in which tumors are implanted at their tissue of origin. By preserving the native anatomical and microenvironmental context, orthotopic models more accurately reflect physiologically relevant tumor growth, local invasion, and metastatic spread. As a result, they provide a more robust and predictive platform for evaluating therapeutic efficacy and informing clinical decision-making.

A Comprehensive Portfolio of Orthotopic Cancer Models

Biocytogen offers a comprehensive portfolio of orthotopic models spanning breast, brain, liver, pancreatic, colorectal, prostate, bladder, and skin cancers.

Biocytogen's Orthotopic Tumor Models

Powered by cutting-edge gene-editing technologies and robust preclinical platforms, Biocytogen’s orthotopic models are optimized for both monotherapy and combination therapy studies. Key capabilities include:

Integrated bioluminescence imaging (BLI) for non-invasive, real-time tumor monitoring
Immune infiltration analysis to assess tumor–immune interactions
Metastasis monitoring to evaluate disease progression and therapeutic impact

Together, these capabilities generate multidimensional, clinically relevant datasets that accelerate the development of antibody therapeutics, antibody–drug conjugates (ADCs), and immuno-oncology programs.

Case Study 1: Orthotopic Liver Cancer Model

Antitumor Activity of Anti-HER2 ADC in the B-Tg (Luc-EGFP) Hep G2 Liver Orthotopic Model

DS-8201 significantly inhibited B-Tg (Luc-EGFP) Hep G2 tumor growth in B-NDG mice. Hep G2 cells (5×10⁵) mixed 1:1 with Matrigel were orthotopically implanted into female B-NDG mice (8-week-old, n=6). Treatment began when imaging signals reached ~2.7×10⁸ p/sec, with dosing shown in the upper panel. Mean ± SEM.

Case Study 2: Orthotopic Brain Cancer Model

Establishment of Orthotopic Glioma Model

The mouse orthotopic glioma model was generated by implanting B-Tg (Luc-EGFP) U-87 MG cells into the caudate putamen of B-NDG mice. Tumor volume and body weight were monitored weekly. Tumor growth increased with minimal body-weight change, confirming successful establishment of the orthotopic glioma model.

Imaging-Based Assessment of Orthotopic Glioblastoma

A) Micro-CT images of B-Tg (Luc-EGFP) U-87 MG tumors in female B-NDG mice scanned 5 days post-inoculation, showing cross-sectional, coronal, and sagittal views with red indicating tumor mass in 3D. B) Dynamic changes in total fluorescence signal at the tumor site. C) Body-weight monitoring. D) H&E staining of tumor tissue.

Accelerate Oncology Drug Development with Biocytogen

By integrating organ-relevant tumor biology with advanced imaging, immune profiling, and metastasis analysis, Biocytogen’s orthotopic tumor model platforms enable more predictive preclinical decision-making. These platforms are designed to help researchers de-risk development programs and advance promising therapeutics toward the clinic with greater confidence.

Partner with Biocytogen to bring clinically meaningful oncology innovations closer to patients!

Frequently Asked Questions (FAQ)

1. What are orthotopic tumor models in oncology research?

Orthotopic tumor models implant tumors into their organ of origin, preserving the native tumor microenvironment. This enables more physiologically relevant growth, invasion, and metastasis, making them highly valuable for preclinical oncology research and translational studies.

2. How do orthotopic tumor models differ from subcutaneous xenograft models?

Unlike subcutaneous xenografts, orthotopic xenograft models grow tumors in the correct anatomical site. This results in more clinically predictive data for cancer drug development, particularly for therapies targeting invasion, metastasis, and immune interactions.

3. What cancer types can be studied using orthotopic tumor models?

Orthotopic tumor models are used across major solid tumors, including breast, brain, liver, pancreatic, colorectal, prostate, bladder, and skin cancers, supporting diverse in vivo oncology studies.

4. How do Biocytogen's orthotopic tumor models support antibody, ADC, and immunotherapy development?

By integrating bioluminescence imaging, immune profiling, and metastasis monitoring, Biocytogen's orthotopic models deliver multidimensional, clinically relevant data to accelerate antibodies, ADCs, and immuno-oncology programs.